
Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.

June 15, 2021
Ten years ago, a seminal paper published by Cytel Founder Cyrus Mehta, introduced the Promising Zone Design to...
Read article

October 1, 2020
Improve Trial Design with Sequential Design and Sample Size
Methods involving Group Sequential Designs are one of the earliest deviations from a traditional two-arm clinical trial...
Read article

June 10, 2020
Group Sequential Designs and Sample Size Re-estimation
Cytel is conducting a webinar series that introduces biostatisticians to some of the more commonly used complex...
Read article

May 27, 2020
Group Sequential Designs and Sample Size Re-estimation
In this blog, we speak with Christopher Jennison, Professor of Statistics at the University of Bath, UK. Professor...
Read article

November 9, 2016
New East Insights Video:Creating an SSR Design
Adaptive sample size re-estimation designs are an important part of the statistician's toolkit. In this first in a...
Read article

September 7, 2016
Overcoming challenges of 'Less Well Understood' Adaptive Designs
In the 2010 draft FDA ‘Guidance for Industry on Adaptive Design Clinical Trials for Drugs and Biologics', the agency...
Read article

August 26, 2016
Sample Size Re-Estimation in Bioequivalence Trials with Small Samples
At the recent JSM in Chicago, Cytel’s Sam Hsaio and Lingyun Liu alongside Genentech's Romeo Maciuca, presented a...
Read article

July 18, 2016
Adaptive Design in the limelight with NEJM article
In order for adaptive designs to reach their potential, it’s critical that knowledge is effectively dissemirnated...
Read article

April 7, 2016
Blinded SSR in early phase biosimilar studies
Francois Beckers, Global Head of Biostatistics & Epidemiology at Merck KGaA joined us at the East User Group Meeting in...
Read article
September 18, 2014
5 times ‘Keep it Simple’ May Be Bad Advice for Clinical Designers
When designing clinical trials, many trial designers are advised to keep the trial simple. Prima facie, the keep it...
Read article

May 13, 2014
De-Risking Drug Development using Adaptive Design
The VALOR trial recently applied a promising zone design to a Phase 3 evaluation of Vosaroxin, a candidate for the...
Read article
May 5, 2014
The Perils of Poor Recruitment
A new JAMA study on discontinued randomized trials in Switzerland, Germany and Canada, reports that poor recruitment...
Read article